Skip to content

Glaukos GKOS Asset turnover

Asset turnover at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.5×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.4×0.0×
AbbVie logo
AbbVieABBV
0.5×+0.1×
Boston Scientific logo
Boston ScientificBSX
0.5×0.0×
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
0.3×0.0×
Exelixis logo
ExelixisEXEL
0.9×+0.1×

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Calculated from Glaukos’s reported figures.

Based on trailing twelve months.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's asset turnover?
Glaukos (GKOS) reported asset turnover of 0.6× in Q1 2026.
How has Glaukos's asset turnover changed year-over-year?
Glaukos's asset turnover increased by 39.2% year-over-year, from 0.4× to 0.6×.
What is the long-term trend for Glaukos's asset turnover?
Over 5 years (2020 to 2025), Glaukos's asset turnover has grown at a 17.1% compound annual growth rate (CAGR), from 0.2× to 0.5×.